Medication info
Kosal Plus Tablet

Kosal Plus Tablet

Prescription medicationTablet
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201706873 · Approved 2017.08.29

Summary

Main use
Treatment of hypertension uncontrolled by monotherapy
Who uses it
Adults · Children
Adult dosage
○ Adults The usual dose of this product is 1 tablet once daily containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This product may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate this product when the expected effect is not achieved with monotherapy. 1. Replacement therapy: Treatment with individually dose-adjusted losartan potassium and hydrochlorothiazide in combination may be replaced with this product. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Initiate treatment with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Initiate treatment with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg, and if blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Administer the usual dose when creatinine clearance is 30 mL/min or higher. Administration is not recommended for patients with more severe renal impairment, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended for patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium of 25 mg cannot be administered using this product.
Children's dosage
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension uncontrolled by monotherapy

  • Hypertension
View approved original text

This medication is used to effectively lower and control blood pressure in patients with hypertension whose blood pressure is not adequately controlled with monotherapy.

Dosage and Administration

Adult dosage

○ Adults The usual dose of this product is 1 tablet once daily containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This product may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate this product when the expected effect is not achieved with monotherapy. 1. Replacement therapy: Treatment with individually dose-adjusted losartan potassium and hydrochlorothiazide in combination may be replaced with this product. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Initiate treatment with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Initiate treatment with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg, and if blood pressure is not controlled after 3 weeks, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Administer the usual dose when creatinine clearance is 30 mL/min or higher. Administration is not recommended for patients with more severe renal impairment, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended for patients with hepatic impairment requiring dose adjustment, because the initial dose of losartan potassium of 25 mg cannot be administered using this product.

Children's dosage

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus when taken during pregnancy, particularly in the second and third trimesters. There is a heightened risk of impaired fetal lung development, skeletal deformities, and kidney problems. If pregnancy is confirmed, the medication should be stopped immediately, and women who may become pregnant should avoid using this drug. This medication should not be used by patients with severe allergies, severely impaired kidney function, severe liver disorders, or certain electrolyte imbalances. Patients with hypersensitivity to sulfonamide drugs or anuria should also avoid this medication. Patients with hypotension, kidney problems, liver disease, diabetes, gout, or cerebrovascular disorders should use this medication cautiously, particularly elderly patients or those with a history of skin cancer. This drug has a blood pressure-lowering effect, and initial use may cause dizziness or drowsiness; in some cases, there is a risk of fainting due to severe hypotension, so caution is needed. It may cause fluctuations in potassium levels, so potassium supplements or potassium-containing foods should not be taken without consulting a physician, and regular checks of serum electrolyte levels and kidney function are required. The hydrochlorothiazide component can cause electrolyte imbalances, elevated blood sugar, hyperuricemia, and rarely acute angle-closure glaucoma or serious skin reactions, so any symptoms that arise should be discussed with a healthcare professional immediately. While taking this medication, precautions should be taken to prevent skin damage from sunlight, and if new skin lesions develop, the healthcare provider should be notified immediately. Caution is necessary when driving or operating machinery due to the potential for dizziness or drowsiness, particularly at the start of treatment or during dosage adjustments. This medication can interact with other antihypertensives, diuretics, and drugs that affect serum potassium, so it is essential to consult with a doctor or pharmacist about other medications being taken. Use in children and adolescents is not recommended as safety and efficacy have not been established.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • kidney failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • lumbago
  • dizziness
Show 178 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin peeling
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • hyperesthesia
  • panic disorder
  • sensory disturbance
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • dizziness
  • dyspnea
  • epistaxis
  • nasal congestion
  • throat discomfort
  • respiratory congestion
  • rhinitis
  • venous obstruction
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • phototoxic reactions
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequent urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • hemolytic anemia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • hyperuricemia
  • muscle spasms
  • restlessness
  • kidney failure
  • kidney dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • hypotension
  • tachycardia
  • angioedema
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythema nodosum
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis
  • hypokalemia
  • hypochloremic metabolic alkalosis
  • thirst
  • dehydration
  • weakness
  • somnolence
  • drowsiness
  • restlessness
  • confusion
  • seizures
  • myalgia
  • cramping
  • muscle fatigue
  • decreased urine output
  • tachycardia
  • nausea
  • vomiting
  • foamy urine
  • arrhythmia
  • hypochloremia
  • dilutional hyponatremia
  • hyperuricemia
  • hyperglycemia
  • acute transient myopia
  • acute angle-closure glaucoma
  • pulmonary edema
  • dyspnea
  • fever
  • worsening lung condition
  • hypotension
  • changes in kidney function
  • decreased urine output
  • progressive azotemia
  • acute renal failure
  • increased blood creatinine levels
  • elevated serum potassium concentration
  • intestinal vascular edema
  • abdominal pain
  • nausea
  • vomiting
  • diarrhea
  • dizziness
  • drowsiness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that blocks light. Additionally, the medication should be kept at room temperature between 1°C and 30°C, not in excessively hot or cold locations.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.